Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy’s Laboratories founder passes away

Dr K. Anji Reddy loses cancer battle

Dr Reddy's Laboratories Dr K Anji ReddyDr K Anji Reddy, the founder and chairman of India's Dr Reddy's Laboratories died last week after a long battle with liver cancer.

The son of a turmeric farmer, he set up the company that bears his name in 1984 and grew the Hyderabad-based firm into one of India's leading pharmaceutical companies.

In 1993, it became the first initiate domestic firm to begin its own basic drug discovery research and, while this has yet to come to fruition, its generics business has gone from strength to strength.

His son, and current managing director of Dr Reddy's Laboratories, Satish Reddy said: “Dr Reddy touched millions of lives through his contribution to the pharmaceutical industry and his philanthropic efforts. In improving access to affordable, high quality medicines and in innovation, his contributions have been extraordinary.”

Dr K Anji Reddy was increasingly focused on philanthropy in the last 15 years, leading initiatives to provide safe rural drinking water and meals to school children and farmers.

Of late, the company has been run by his son K Satish Reddy, as managing director and COO, and his son-in-law G V Prasad, who is the vice chairman and CEO.

A BSc graduate from Bombay University with specialisation in Pharmaceutical Science and Fine Chemicals, Dr Reddy obtained his PhD in Chemical Engineering from National Chemical Laboratory, Pune.

Soon after his studies, he served in the state-owned IDPL before he founded his own company in 1984.

Dr Reddy served as a member of the Prime Minister's Council on Trade & Industry, Government of India and was honoured with one of India's highest civilian awards, the Padma Bhushan, in April 2011.

18th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics